Eric Legius is a clinician scientist. He was the head of Human Genetics Department of the University of Leuven from 2001-2005 and from 2011- 2016. He was clinical director of the Centre for Human Genetics of the University Hospital of Leuven from 2011 till 2021. His research was targeted towards neurofibromatosis type 1 and related conditions. He contributed successfully towards the understanding of the molecular aetiology of a number of tumours in neurofibromatosis type 1 (NF1) . He was involved in the identification of the importance of the polycomb repressor complex type 2 for the development of malignant peripheral nerve sheath tumours in NF1. In 2007 his research team identified a new condition resembling neurofibromatosis type 1, now known as Legius syndrome (autosomal dominant condition caused by a heterozygous mutation in SPRED1). Eric Legius contributed to the revised diagnostic criteria for NF1, Legius syndrome, and the schwannomatoses (NF2-related, SMARCB1-related, LZTR1-related). He was also a senior author on the recent publication of guidelines by the European Reference Network GENTURIS concerning the surveillance and treatment of NF1-related tumours. Eric Legius retired from active patient management in October 2023.